Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zentiva, k.s., Česká republika - diltiazem - 83 - vasodilatantia

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

belupo lijekovi i kozmetika d.d., chorvátska republika - vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

sandoz pharmaceuticals d.d., slovinsko - vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

zentiva, k.s., Česká republika - vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

krka, d.d., novo mesto, slovinsko - vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

teva b.v., holandsko - vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

g.l. pharma gmbh, rakúsko - vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

stada arzneimittel ag, nemecko - vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

vipharm s.a., poľsko - vildagliptín - 18 - antidiabetica (vrÁtane inzulÍnu)

Európska únia - slovenčina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.